testosterone

AssetSmall moleculeAlso AndroGel 1.62%, Testosterone Gel 1.62%, Testosterone (T) Gel, Natesto

Oral testosterone replacement therapy acting as an androgen receptor agonist.

Stage: Approved
Modality: Small molecule
Target: Lipid and ceramide metabolism
Indications: 19
Trials: 230
Developers: 17

Indications

19

Hormone deficiency
Approvedaccessdata.fda.gov7 Oct 2026
Hypoactive sexual desire disorder
Approvedema.europa.eu7 Oct 2026
Hypogonadism
Approvedaccessdata.fda.gov7 Oct 2026

16 more

Targets and what it contains2
Owner and partners18
Trials230
Evidence for its targets3
Competitors12
Aging relevance1
Signals9

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026 · 70 sources